Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tovorafenib

FDA-approved product (tablet, oral), marketed as Ojemda.

Registered studies
16
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tovorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Low grade glioma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

16registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tovorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tovorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

    NCT07206849 · start 2026-11

    Registered record
    Registry ID
    NCT07206849
    Conditions
    High Grade Glioma (HGG) of the Brain With BRAF Aberration; High Grade Glioma (III or IV); Diffuse Intrinsic Pontine Glioma; High Grade Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma; Metastatic Brain Tumor
    Interventions
    Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2037-11
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Glioma (HGG) of the Brain With BRAF Aberration; High Grade Glioma (III or IV); Diffuse Intrinsic Pontine Glioma; High Grade Glioma +3 more
    InterventionTovorafenib
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV

    NCT07635992 · start 2026-06-01

    Registered record
    Registry ID
    NCT07635992
    Conditions
    HIV (Human Immunodeficiency Virus)
    Interventions
    Ibalizumab Combined with Chidamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2028-12-31
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV (Human Immunodeficiency Virus)
    InterventionIbalizumab Combined with Chidamide
    PhasePhase 1
    Registry statusNot yet recruiting

  • Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

    NCT06965114 · start 2026-05-29

    Registered record
    Registry ID
    NCT06965114
    Conditions
    Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia; Refractory Hairy Cell Leukemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cladribine; Computed Tomography; Rituximab; Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-05-29
    Completion
    2030-03-01
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHairy Cell Leukemia; Recurrent Hairy Cell Leukemia; Refractory Hairy Cell Leukemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cladribine +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

    NCT07441707 · start 2026-03-10

    Registered record
    Registry ID
    NCT07441707
    Conditions
    Low-grade Glioma
    Interventions
    Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2026-03-10
    Completion
    2030-07-31
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-grade Glioma
    InterventionTovorafenib
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

    NCT05828069 · start 2024-03-28

    Registered record
    Registry ID
    NCT05828069
    Conditions
    Recurrent Langerhans Cell Histiocytosis; Refractory Langerhans Cell Histiocytosis
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Echocardiography Test; FDG-Positron Emission Tomography and Computed Tomography Scan; Lumbar Puncture; Multigated Acquisition Scan; Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-28
    Completion
    2028-09-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Langerhans Cell Histiocytosis; Refractory Langerhans Cell Histiocytosis
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

    NCT06381570 · start 2024-03-21

    Registered record
    Registry ID
    NCT06381570
    Conditions
    Low-grade Glioma
    Interventions
    Tovorafenib; Vinblastine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-03-21
    Completion
    2029-03-21
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-grade Glioma
    InterventionTovorafenib; Vinblastine
    PhaseEarly phase 1
    Registry statusRecruiting

  • DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

    NCT05566795 · start 2023-02-27

    Registered record
    Registry ID
    NCT05566795
    Conditions
    Low-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma
    Interventions
    Tovorafenib; Chemotherapeutic Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-02-27
    Completion
    2031-06
    Enrolment
    418

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma
    InterventionTovorafenib; Chemotherapeutic Agent
    PhasePhase 3
    Registry statusActive not recruiting

  • Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

    NCT05465174 · start 2022-09-12

    Registered record
    Registry ID
    NCT05465174
    Conditions
    Craniopharyngioma, Child; Craniopharyngioma; Recurrent Craniopharyngioma
    Interventions
    Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-09-12
    Completion
    2028-03-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCraniopharyngioma, Child; Craniopharyngioma; Recurrent Craniopharyngioma
    InterventionTovorafenib
    PhasePhase 2
    Registry statusRecruiting

  • Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

    NCT07121829 · start 2022-05-02

    Registered record
    Registry ID
    NCT07121829
    Conditions
    Melanoma; Solid Tumor; Pilocytic Astrocytoma; Non Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; MAP Kinase Family Gene Mutation; RAS Mutation; RAF Mutation; MEK Mutation
    Interventions
    Tovorafenib; Tovorafenib Drug: Pimasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-05-02
    Completion
    2024-12-18
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Solid Tumor; Pilocytic Astrocytoma; Non Small Cell Lung Cancer +6 more
    InterventionTovorafenib; Tovorafenib Drug: Pimasertib
    PhasePhase 1
    Registry statusTerminated

  • Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

    NCT04985604 · start 2021-07-15

    Registered record
    Registry ID
    NCT04985604
    Conditions
    Melanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusion; CRAF Gene Fusion; CRAF Fusion; RAF1 Gene Fusion; RAF1 Fusion; Thyroid Cancer, Papillary; Spitzoid Melanoma; Pilocytic Astrocytoma; Pilocytic Astrocytoma, Adult; Non Small Cell Lung Cancer; Non-Small Cell Adenocarcinoma; Colorectal Cancer; Pancreatic Acinar Carcinoma; Spitzoid Malignant Melanoma; Bladder Cancer; Bladder Urothelial Carcinoma; MAP Kinase Family Gene Mutation; RAF Mutation
    Interventions
    Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-07-15
    Completion
    2024-07-08
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification +19 more
    InterventionTovorafenib
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    NCT04775485 · start 2021-04-22

    Registered record
    Registry ID
    NCT04775485
    Conditions
    Low-grade Glioma; Advanced Solid Tumor
    Interventions
    Tovorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-22
    Completion
    2027-05-31
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-grade Glioma; Advanced Solid Tumor
    InterventionTovorafenib
    PhasePhase 2
    Registry statusRecruiting

  • DAY101 In Gliomas and Other Tumors

    NCT03429803 · start 2018-02-27

    Registered record
    Registry ID
    NCT03429803
    Conditions
    Low-grade Glioma
    Interventions
    DAY101
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-27
    Completion
    2025-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-grade Glioma
    InterventionDAY101
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

    NCT02723006 · start 2016-06-22

    Registered record
    Registry ID
    NCT02723006
    Conditions
    Melanoma
    Interventions
    TAK-580; TAK-202; vedolizumab; nivolumab; ipilimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-06-22
    Completion
    2018-05-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionTAK-580; TAK-202; vedolizumab; nivolumab +1 more
    PhasePhase 1
    Registry statusTerminated

  • A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

    NCT02327169 · start 2015-01-14

    Registered record
    Registry ID
    NCT02327169
    Conditions
    Advanced Nonhematologic Malignancies
    Interventions
    MLN2480; MLN0128; Alisertib; Paclitaxel; Cetuximab; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01-14
    Completion
    2018-07-02
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Nonhematologic Malignancies
    InterventionMLN2480; MLN0128; Alisertib; Paclitaxel +2 more
    PhasePhase 1
    Registry statusCompleted

  • Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

    NCT01425008 · start 2011-09-15

    Registered record
    Registry ID
    NCT01425008
    Conditions
    Melanoma; Metastatic Melanoma; Solid Tumor; Neoplasm
    Interventions
    MLN2480
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09-15
    Completion
    2018-10-16
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Metastatic Melanoma; Solid Tumor; Neoplasm
    InterventionMLN2480
    PhasePhase 1
    Registry statusCompleted